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Abstract
Background: While investment in the development of Tuberculosis (TB) treatment strategies is essential, it cannot
be assumed that the strategies are affordable for TB patients living in countries with high economic constraints.
This study aimed to determine the economic consequences of directly observed therapy for TB patients.
Methods: A cross-sectional cost-of-illness analysis was conducted between September to November 2015 among
576 randomly selected adult TB patients who were on directly observed treatment in 27 public health facilities in
Addis Ababa, Ethiopia. Data were collected using interviewer-administered questionnaire adapted from the Tool to
Estimate Patients’ Costs. Mean and median costs, reduction of productivity, and household expenditure of TB patients
were calculated and ways of coping costs captured. Eta (η), Odds ratio and p values were used to measure association
between variables.
Results: Of the total 576 TB patients enrolled, 43 % were smear-positive pulmonary TB (PTB), 17 % smear-negative PTB,
37 % Extra-PTB and 3 % multi-drug resistant TB cases. Direct (Out-of-Pocket) mean and median costs of TB illness to
patients were $123.0 (SD = 58.8) and $125.78 (R = 338.12), respectively, and indirect (loss income) mean and median
costs were $54.26 (SD = 43.5) and $44.61 (R = 215.6), respectively. Mean and median total cost of TB illness to patient
were $177.3 (SD = 78.7) and $177.1 (R = 461.8), respectively. The total cost had significant association with patient’s
household income, residence, need for additional food, and primary income (P <0.05). Direct costs were catastrophic
for 63 % of TB patients, regardless of significant difference between gender (P = 0.92) and type of TB cases (P = 0.37).
TB patients mean productivity and income reduced by 37 and 10 %, respectively, compared with pre-treatment level,
while mean household expenditure increased by 33 % and working hours reduced by 78 % due to TB illness. Income
quartile categories were directly correlated with catastrophic costs (η = 0.684).
Conclusion: Despite the availability of free-of-charge anti-TB drugs, TB patients were suffering from out-of-pocket
payments with catastrophic consequences, which in turn were hampering the efforts to end TB. TB patients in
resource-limited countries deserve integrated patient-centered care with comprehensive health insurance coverage,
financial incentives, and nutrition support to reduce catastrophic costs and retain them in care. Such countries should
induce home-based directly observed therapy programs to reduce costs due to attending health facilities, intensify
home treatment of critically-ill patients with impaired mobility, and reduce the spread of TB due to patients traveling
to seek care.
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Background
Integrated, patient-centered TB care and prevention is
recognized as a major pillar in the post-2015 global TB
strategy which envisions a world free of TB by 2035.
The pillar’s core value is early detection, treatment and
prevention of TB to ensure that all TB patients have
equal, unhindered access to affordable services and are
fully engaged in their care [1]. Although this pillar puts
patients at the heart of service delivery, its implementa-
tion in High TB Burden Countries (HBC) is projected to
demand complex resources and targeted efforts [2, 3].
TB care strategies in these settings have contended to
deliver TB services free-of-charge, but economic chal-
lenges experienced by TB patients continued to hamper
the system [4–6]. While implementation of the Directly
Observed, Treatment Short course (DOTS) strategy
(1994–2005) and the Stop TB Strategy (2006–2015) had
significant contributions to the prevention and control
of TB, they were also reported to pose a substantial eco-
nomic burden on patients in terms of cost and afford-
ability [7–10]. Out-of-Pocket (OOP) payments due to
transportation, accommodation and food to get treat-
ment at health facility aggravate economic crisis of TB
patients: impacting their adherence to treatment [11–13]
and forcing them to stop working, sell their properties,
borrow money and reduce their overall income [14–17].
The initial milestone of the post-2015 global End TB
strategy is to reduce TB deaths by 35 %, cut TB incidence
rate by 20 %, and reduce TB-affected families facing cata-
strophic costs due to TB to 0 % between the years 2015
and 2020 [1]. Committed governments in HBCs, such as
Ethiopia, which were able to achieve the Millennium
Development Goal (MDG) 6 target of reducing the TB
incidence rate, are also pledged to attain the post-2015 TB
targets. In Ethiopia, the decline in incidence, prevalence
and deaths related to TB [18] was an impressive gain in
achieving the 2015 MDG 6 target. However, the country
still ranks 3rd in Africa and 10th among the 22 HBCs in
the world [19], and TB remains one of the leading causes
of mortality [20]. Previous studies from different regions
of Ethiopia reported that the cost of TB is a major barrier
for patients to successfully complete care in Directly-
Observed Therapy (DOT) [8, 21, 22].
Ensuring patient-centered TB care and prevention in
HBCs ought to minimize financial burdens for TB pa-
tients and ratify that TB patients and affected families
receive social protection interventions [6]. Understanding
the direct and indirect costs of TB, their implications and
costs of coping strategies for TB patients is essential to
develop affordable TB care services in HBCs and to sup-
port poverty mitigation activities that could be grounded
due to TB care strategies. This study was conducted in
support of the integrated, patient-centered TB care and
prevention pillar of the post-2015 TB strategy. It aimed to
determine the economic consequences of the DOT
strategy for TB patients and inform effective interventions
required to successfully implement the end TB strategy in
HBCs.
Methods
A cross-sectional cost-of-illness analysis was conducted
among adult TB patients who were attending TB care
and treatment services.
Study setting and participants
The study was conducted in public health facilities in
Addis Ababa - the capital city administration of Ethiopia.
The city administration had a total population of about
3.2 million [23] and a population density of 5 271 per-
sons per Km2 [18]. The employment to population ratio
was 45.86 while unemployment was 25 % [23]. Under
the Addis Ababa city government, there were 96 public
health facilities (90 health centers and six hospitals) of
which 88 (92 %) were providing DOT services [24]. For
this study, a list consisting of the 88 health facilities was
received from the Addis Ababa City Government Health
Bureau and 30 % (n = 27) of them were randomly se-
lected using lottery method.
All TB patients who were detected as new cases in
public and private health facilities in Addis Ababa (n = 7
298) were taken as the total population of the study.
From this, all adult TB patients in the selected study fa-
cilities who were taking DOT services, at least for a
month and not beyond the intensive phase of TB treat-
ment (n = 1 673) were purposively selected as the study
population to minimize recall bias. Sample size was cal-
culated using single proportion formula [25], with 0.05
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error allowance, 1.96 confidence level at 95 %, 0.05 level
of catastrophic cost of OOP payments significance, 5 %
contingency for non-response rate, and a design effect of
1.5. With this, the total sample size was calculated to be
604. Current TB registration books were reviewed at
each study facility to determine the estimated TB case-
loads and proportionally allocate the calculated sample
site to each study facility.
Data collection tool and techniques
Data were collected using interviewer-administered
questionnaire comprising open- and close-ended ques-
tions in eight sections. The questionnaire was customized
from a standardized tool to estimate TB patients’ costs
developed by the World Health Organization (WHO),
KNCV Tuberculosis Foundation, and the Japan Anti-
Tuberculosis Association [26]. This tool was used to aid
estimate the total costs of TB patients, guardian costs, re-
duction of productivity, and coping costs by adapting it to
the local setting. The tool was translated to Amharic then
backed to English.
The first section of the study questionnaire captured the
“total costs” of TB illness to patient, in which direct and
indirect medical (pre-diagnostic, diagnostic, and treat-
ment) costs were included. In the first part of this section,
items explaining the direct and indirect pre-diagnostic
and diagnostic costs were captured to determine how
much costs TB patients were incurred for each of their
visits to health facility before they were identified as TB
cases, including the visit when they actually received their
diagnosis. The pre-diagnostic/diagnostic direct costs
include costs for laboratory, X-ray, and drugs, while the
indirect costs include costs for travels, food, accommoda-
tion, healthcare provider, administrative (consultative/
registration), and for their time. This first part of this sec-
tion also captured data to determine if insurance reim-
bursements whether applicable including reimbursed
amount of the cost. In the second part of this section,
items explaining the direct and indirect treatment costs
were included. These costs had two components in the
questionnaire: costs for ant-TB drug pick-up and costs for
treatment follow-up. Costs for ant-TB drug pick-up was
aimed to determine the frequency of travel, distance from
facility, average length of stay, cost per round trip, cost of
food per round trip, administrative costs, and accommo-
dation costs of TB patients when taking anti-TB drugs.
While costs for treatment follow-up was aimed to assess if
TB patients were visiting health facility in addition to their
regular visit schedules and determine associated costs.
Costs for ant-TB medications were excluded from this cat-
egory as this cost was fully covered by the Ethiopian gov-
ernment for all TB patients.
The second section of the questionnaire captured the
total costs of guardians, which were for someone who
accompanies the patient to the health facility or other
visits because the TB patient cannot go by himself/herself.
The questionnaire had captured data to determine if TB
patients were going with guardians, and if applicable, the
reason, how frequent, at which phase (pre-diagnostic/
diagnostic/treatment), and how much a guardian was
earnings per day.
The third section of the questionnaire was hospitalization
cost which aimed to determine if TB patients had been
hospitalized before or during their TB treatment and, if
applicable, the length of stay and direct and indirect costs
associated with it.
The fourth section was costs of food supplements for
nutrition support to determine if TB patients were buy-
ing any supplements for their diet because of TB ill-
nesses and, if applicable, what kind of items they have
bought and who much money they spent.
The fifth section was health insurance. TB patients
were asked if they have any kind of private or govern-
ment health/medical insurance scheme and, if applic-
able, the type of insurance, and if reimbursements were
made and the amount for any costs related to the TB ill-
ness which were to be cross-checked with the first sec-
tion in the questionnaire.
The sixth section was coping costs, which were costs
to meet daily requirements despite extra expenditures or
loss of income, which include the sale of assets, taking
up debt, saving on food or other items, taking a child
out of school to care for the patient or taking up another
job. TB patients were asked if they paid all the costs by
themselves for TB illness, borrow any money to cover
costs due to the illness and if yes how much and from
whom and interest rate on the loan, ever leased anything,
and sold any of their property to finance the cost of the
TB illness and if yes the type of item with its market value
and the actual earning from the sale of properties.
The seventh section was about income loss as well as
income and affordability to TB treatment and healthcare.
It had had multiple questions aimed at determining if
TB patients stay away from work and loses income as a
result of TB illness and estimate the total income loss
due to TB illness and the impact costs had on patients.
The eighth section was for socioeconomic questions
which aimed at capture TB patients’ data regarding the
type of TB infection, dates TB treatment is started, total
duration of planned treatment, treatment status, and
socio-demographic status including average monthly in-
come, occupation, household, and highest level of educa-
tion. Household was referred to a family which consists
of one or more people who live in the same dwelling
and also share at meals or living accommodation.
The questionnaire was pre-tested with 27 TB patients
who were representative of the study’s target group.
After full informed consent obtained, TB patients were
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interviewed at study health facilities when they came
to take their daily medications until the required num-
ber of participants were recruited at each facility.
Ethical clearance to conduct this study was received
from the institutional research ethics review commit-
tee of Debremarkos University and the Addis Ababa
City Administration Health Bureau.
Data analysis and definition of measurements
Data were entered into Statistical Packages for Social
Science (SPSS), version 20, manufactured by IBM,
Chicago, IL, USA to convert to electronic data. All the
costs and income figures collected in Ethiopian cur-
rency (birr) were standardized to United State Dollar ($)
with average exchange rate for the dates during which
data were collected (birr 20.8979.8 = $1). Descriptive sta-
tistics such as mean, standard deviation (SD), median,
range (R), and percentages were computed to explain the
variables. P values, Eta (η), and Odds ratio were used as
the measure of association between variables, where ap-
propriate. One-way sensitivity analysis [27] was carried
out on selected cost items to assess the variations in total
costs of TB patients with their possible options. For re-
gression analysis, the total median cost was used as a cut-
off point to dichotomize the total cost into low and high
payee. Inter-method regression model was used.
The “total cost” was calculated by addition of the en-
tire “direct” and “indirect” costs of TB illness to patient.
The “direct cost” was calculated by addition of any pay-
ment effected in relation to medical and non-medical
costs. The “medical costs” were the sum of OOP pay-
ments for TB diagnosis and treatment made by TB
patients in a given household (purchase of medicines,
payments for diagnostic tests, net of reimbursements),
while the “direct non-medical costs” were OOP pay-
ments related to the use of TB health services (payments
for transport, lodging and food) before and during TB
diagnosis and treatment. The “indirect costs” were TB
patient or guardian lost income due to TB health-care
seeking and hospitalization during the TB episode. It
was calculated by multiplying the time that the patient
did not work with the average individual take home
earning before TB.
“Catastrophic costs” was calculated based on WHO’s ex-
planation: whenever the out-of-pocket costs of TB illness
are greater than or equal to 40 % of a TB patient’s house-
hold non-subsistence annual income [28] i.e. whenever
the proportion of the ability to pay to out-of-pockets is
greater or equal to 40 % with the consequence that the
household suffer the burden of TB disease. Indirect
costs of care and income loss are not included as WHO
explains.
“Reduced productivity” was measured by calculating
the difference in the actual performance of TB patients
before and during TB illness. It was the number of hours
a TB patient had been working per day when s/he was
healthy minus the number of hours a TB patient was
working per day when s/he falls to TB illness.
Regarding treatment phases, “pre-treatment” was the
period of time from self-reported onset of TB-related
symptoms until treatment initiation. “Intensive phase”
was the first two consecutive months of TB treatment.
“Continuation phase” was the four consecutive months
immediately following the intensive treatment phase.
“During treatment” was the period of time spanning
from the beginning of the intensive treatment phase to
the end of continuation treatment phases.
Results
Socio-demographic characteristics
Of the total 604 TB patients accessed, 576 (95 %) were
responded to the questionnaire. Fifty-three percent were
male, 90 % live in urban area, and 62.5 % employed,
18.1 % house wives and 11 % unemployed (Table 1). The
minimum household monthly income was in the range
$14.5–63.40 for 25 % of TB patients, while the max-
imum was in the range $148.83–335.00 for 25 % of TB
patients.
Based on their history of TB diagnosis, 248 (43 %) were
smear-positive PTB cases, 96 (17 %) smear-negative PTB
cases, 216 (37 %) E-PTB cases, and 16 (3 %) MDR-TB
cases. Regarding their TB treatment outcome, 76 % were
newly diagnosed, 17 % relapse, 3 % treatment failure, 3 %
transfer in, and 1 % treatment default.
Cost of TB
The direct (OOP) mean and median costs of TB illness
to patients during DOT were $123.0 (SD = 58.8) and
$125.78 (R = 338.12), respectively, and the indirect (loss
income) mean and median costs were $54.26 (SD = 43.5)
and $44.61 (R = 215.6), respectively. With these, the mean
and median total costs of TB illness to patient during
DOT were $177.3 (SD = 78.7) and $177.1 (R = 461.8), re-
spectively (Table 2). Among the OOP, 37 % was for food
supplements for nutrition support and 33.6 % was for hos-
pital related direct costs.
The total cost of TB illness to patients had significant
association with patient’s household income, residence,
need for additional food, and primary income (P <0.05)
(Table 3).
Medical and non-medical cost
Mean medical and non-medical costs of TB illness to
patients $18.9 (SD = 14) and $104 (SD = 55.5), respect-
ively. The medical costs constituted only 15 % of the
total direct cost, while the rest 85 % was for non-
medical costs. The non-medical direct mean follow up
costs for six month was $23 (SD = 24), out of which
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73 % was disbursed for a daily follow up in the first two
consecutive months from confirmation of TB (Table 4).
After a patient is diagnosed as TB case, the direct mean
treatment follow up costs was $23.5. Seventy-six percent
of the direct mean direct treatment follow-up costs was
for direct observations while a patient was taking TB
medications at the health facility during an intensive
phase; of which 68 % was incurred for food and water
while a patient was travelling to the health facility and
the rest 32 % was for transportation (Table 4).
One-way sensitivity analysis
The total exclusion of additional food costs for nutrition
support from the out-of-pocket cost could reduce the
mean total costs of TB from $177.30 (SD = 78.7) to $104
(SD = 58.8). Reduction in frequency of treatment follow
ups and avoidance of unscheduled follow ups also had
substantial contributions in the reduction of OOP pay-
ments (Table 5).
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Permanent employee 97 16.8
Self-employee 149 25.9
Table 1 Socio-demographic characteristics of TB patients on DOT
(Continued)
Temporary employee 114 19.8




$ United States dollar; amajor town and cities; bvillages and hamlets; cwithout
formal house such as living on street; dGurage, Silte, Sidama
Table 2 Cost of TB illness to patients under DOT
Costs of TB illness to patients N Mean (SD) Median (R)
Direct costs (OOP)
Pre diagnostic and diagnostic 576 24.71 (18.4) 20.10 (134.7)
Anti TB treatment follow up 576 23.42 (24.6) 22.97 (287.1)
Hospital admission related 96 66.04 (67.5) 44.26 (353.9)
Guardian/ accompany 388 1.49 (1.79) 0.96 (10.0)
Un scheduled additional
follow up
104 8.36 (8.5) 5.70 (57.32)
Additional food 472 72.36 (46.7) 83.26 (201.0)
Direct cost total 576 123.0 (58.8) 125.78 (338.12)
Indirect costs (loss income)
Pre diagnosis and diagnosis 360 14.31 (18.7) 11.32 (182.47)
Treatment follow up cost 360 41.04 (31.6) 30.51 (43.07)
Guardia/ accompany 388 5.19 (8.9) 0 (215.57)
Hospital stay 96 16.38 (15.8) 12.80(74.2)
Indirect costs total 360 54.26 (43.5) 44.61 (215.6)
Total cost (Direct + Indirect) 576 177.30(78.7$) 177.14 (461.8)
Figures are computed at Ethiopia average National Bank exchange rate of Birr
20.8979.8 to $1 in October 2015
SD Standard deviation, R Range
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Catastrophic costs
Among the 576 TB patients in this study, OOP pay-
ments were catastrophic for 63 % of TB patients. The
proportion incurring catastrophic costs did not have
significance difference between gender (P = 0.92) and
type of TB cases (P = 0.37). The proportion incurring
catastrophic costs was significantly different across
number of individuals in a household and across differ-
ent household monthly income quartiles (P <0.001).
The highest income quartile categories were directly
correlated with reduction of catastrophic costs of OOP
payments (η = 0.684). For TB patients with the highest
household income quartile group, OOP payments was
catastrophic only for 5.3 % of patients, whereas for
those with the lowest household income quartile group
it was catastrophic for 99.5 % of patients.
The study analyzed the association of different variables
with catastrophic level of OOP payment and found no as-
sociation between TB patients with different cases of TB,
level of education, gender, went un-scheduled additional
follow-up, presence of guardian, borrowed money, sold
and leased assets (P >0.05). Whereas marginally significant
associations of catastrophic costs were found between TB
patients with different age groups (P = 0.056) and area of
residence (P = 0.05) (Table 6).
Coping costs
Only 56 (9.7 %) of TB patients had any kind of medical
insurance scheme such as employee insurance for 24
(42.8 %) patients, community based health insurance for
8 (14.3 %) of patients, private health insurance for 16
(28.6 %) of patients and government-driven free treat-
ment scheme for 8 (14.3 %) of patients. For majority
(90 %) of TB patients, OOP payments were covered by
their family members and for the rest 10 % by their
neighbors and nearby friends. Among the total 576 TB
patients, 18 % borrowed money to cope TB costs, of
whom 34 % from neighbors, 26 % from friends, 23 %
Table 3 Factors associated with high cost of TB illness to patients under DOT





Lower boundary Upper boundary
Family income($) 0.033
< 117 162 139 1.847 1.051 3.248
> 117 109 162 1.00
Residence <0.001
Urban 266 254 1.00 1.651 6.024
Rural 18 36 3.154
Additional food cost <0.001
Yes 208 264 5.733 3.314 9.920
No 78 26 1.00
Primary income earner 0.010
Patient 157 167 3.876 1.382 10.872
Wife/mom 8 12 6.884 1.732 27.357
Husband/father 101 105 3.532 1.199 10.404
Son/daughter 20 6 1.00
Cost covered by 0.029
Patient and/or family 251 270 0.412 0.299 0.98
Others (friends, neighbor) 35 20 1.00
Table 4 Direct treatment follow up costs of TB illness to patient under DOT
Intensive phase Continuation phase Total phase (6 months)
Transport Food & water Total Transport Food & water Total Transport Food & water Total
Mean 5.38 11.79 17.18 1.96 4.29 6.25 7.34 9.67 23.42
SD 12.0 12.5 18.0 4.4 4.6 24.7 16.5 13.9 24.3
Median 4.21 10.53 16.84 1.53 3.83 6.13 5.74 7.65 22.97
Range 210.55 105.27 210.5 76.56 38.28 76.6 287.11 210.5 287.11
SD Standard deviation
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from relatives, and 17 % from organizations. None of
them borrowed with interest. Eleven percent (11 %) of
TB patients sold their properties to cope TB costs, and
house utensils was the major properties TB patients
were selling for coping costs.
Implications
The mean and median drug collection time a TB patient
spent per visit was 1.5 h (SD = 0.6 h) with a range of
3.5 h five times a week during intensive phase and once
in a week for continuation phase of TB treatment.
Among TB patients who were employees (n = 360), 78 %
reduced working hours due to TB illness. Consequently,
their mean productivity reduced by 37 % (SD = 22) and
income by 10 % (SD = 30), and mean household expend-
iture increased by 33 % (SD = 25) (Fig. 1).
Among TB patients who were employees and/or stu-
dents (n = 484), 240 (59.5 %) ever stopped working and/or
going to school due to TB illness at least for a day, of
whom 22 % gave up for more than 8–34 days and 8.5 %
totally stopped working. One hundred twenty one (21.7 %)
of guardians were accompanying TB patients to go to
health facilities by quitting their income earning jobs,
while 95 (16.5 %) of TB patients had care giver at home, of
which 73 (77 %) were quitting their income earning jobs
to provide care of the TB patient at home.
Discussion
The Ethiopian FMoH has given due attention and prior-
ity to the treatment, prevention and control of TB with
technical and financial support from partners in the
field. Because of the development and implementation
of countrywide strategies which fully aligned with the
globally recommended Stop TB strategy, Ethiopia
augmented ability to achieve all TB related millennium
development goals; reduced the incidence by 44 %,
prevalence by 50.5 % and deaths related to TB by 64 %
from 1990 baseline [29]. However, the economic
Table 5 One-way sensitivity analysis of total costs of TB under DOT
n Mean (SD) Median (R)
If additional food cost not considered, to be zero or food support
practiced to TB patients
Direct cost 576 50.60 (3.2) 45.85 (306.06)
Indirect cost 360 54.26 (43.5) 44.62 (215.6)
Total cost 576 104.95 (58.8) 92.70 (423.54)
If treatment follow-up phases are changed from every day to every
week in intensive phase and from every week to every month for
continuation phase
Direct cost 576 104.26 (55.0) 107.40 (306.1)
Indirect cost 360 44.60 (6.0) 38.25 (215.9)
Total cost 576 148.82 (64.0) 145.65 (420.2)
No unscheduled follow-up considered, no additional follow-up cost
Direct cost 576 115.70 (73.0) 120.78 (208.6)
Indirect cost 360 54.26 (42.3) 44.62 (215.6)
Total cost 576 169.96 (69.0) 165.50 (463.8)
If all TB patient diagnosis and treatment completed at out-patient
department, without admission related cost
Direct cost 576 110.00 (40.3) 112.60 (208.8)
Indirect cost 360 42.89 (8.2) 32.78 (203.3)
Total 576 136.00 (29.9) 145.18 (455.70)
Table 6 Factors associated with catastrophic costs of TB illness to patients
Variable Catastrophic costs AOR (95 % Confidence interval) P value
Yes (n) No (n) Lower boundary Upper boundary
Additional food cost incurred < 0.001
Yes 315 157 4.555 2.050 10.119
No 46 58 1.00
Borrowed 0.036
Yes 75 29 2.253 1.057 4.804
No 286 186 1.00
Monthly family income ($) <0.001
< 117 275 26 48.038 22.581 74.190
> 117 82 189 1.00
Ever stopped working < 0.001
Yes 231 107 1.918 1.351 2.721
No 130 108 1.00
Presence of care giver at home < 0.001
Yes 45 50 0.430 0.274 0.677
No 316 165 1.00
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consequences of the various TB strategies for patients
had been a debatable issue. The cost-of-illness analysis
we conducted proves that TB patients living in central
Ethiopia are facing multiple challenges due to the high
cost of the DOT strategy, and the cost ($177.3) was even
quite higher than the $25 estimated for PTB patients in
Southern region [30] and the $53 estimated for PTB pa-
tients in 10 district areas of Tigray region [31] and in
Ethiopia, though it was by far lower than the $847 esti-
mated for low-income countries [6]. The differences
might arise from different study settings, time of deter-
mination as cost is time-sensitive, and the type of TB
cases included in the studies.
This study shows that the existing DOT strategy which
requires frequent use of healthcare facilities for TB treat-
ment has a significant impact on the total cost of illness to
TB patients. The one-way sensitivity analysis reveals that
there is a 15 % reduction of OOP payments if DOT sched-
ule is rearranged from daily to weekly for intensive phase
and from weekly to monthly for continuation phase. Stud-
ies from different countries, including Ethiopia, also re-
vealed that DOT is one of the major factors that lead to
high cost of TB illness to patients as long as travelling to a
health facility is tied with transport and food costs while
on the way [3, 17, 31–38]. The challenge could enforce TB
patients to discontinue treatment and acquire MDR and
XDR TB, even when they understand the consequences of
this. This needs careful policy designs that TB patients de-
serve an integrated patient-centered care with financial in-
centives to retain them in care. Some studies conducted in
Ethiopia also recommend community-based treatment of
TB patients through health extension workers [30] and
bringing services closer to patients [12] to reduce OOP
payments and retain TB patients in care.
Similarly, the study illustrated that OOP payments
were catastrophic to majority (63 %) of TB patients. The
level of this catastrophic cost had a significant change
across different income quartile groups (P <0.05), similar
to another multi-center study conducted in Ghana, Viet
Nam and the Dominican Republic [37]. The estimated
costs for direct observation of patients at health facilities
and for pre-diagnostic and diagnostic from the total dir-
ect cost of TB illness to patients was nearly similar to
studies reported in Zambia [15] and Burkina Faso [33],
but lower than the estimate in South Africa [34]. This
study didn’t show association between hospitalization
cost and total cost, while other studies held in differ-
ent settings reported an association between the two
as the major cause for the higher costs of TB treat-
ment [30, 31].
This study shows that the economic consequence of
TB illness to patients was beyond OOP payments. In-
come loss constituted 30 % of the total cost of TB illness
to patients, which was quite lower than the 60 % re-
ported for low and middle-income [6]. The difference
could arise from the difference of study participants’
average monthly income between study participants of
this study and middle and low income countries where
the review assessed. Moreover, 38 % of this study partici-
pant was students and pensioners’ without income earn-
ing jobs. Furthermore, the implication was reflected to
the guardian of TB patients, with a significant number
of guardians quitted their income earning jobs to accom-
pany TB patients and give care at home. There was also a
subsequent reduction of productivity and increment of
household expenditure due to TB illness to patients.
These call for an urgent need of financial incentives for
TB patients in Central Ethiopia to enforce adherence to
treatment. Financial incentives proved to be effective in
improving treatment completion and reducing default
rates among TB patients [30, 36].
Despite other studies [3, 30], in this study, age, gender,
and educational status were not associated with total
and catastrophic costs of TB illness to patients. The
Fig. 1 Implications of TB illness to patients
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factors associated with high total cost due to TB in were
family income, place of residence, payer of the cost, pri-
mary income earner, cost payer and additional food cost.
TB patients who had lower income were less likely to
pay high cost for their TB illness when compared to TB
patients with high income, reflecting that TB patients
with low income required a more financial incentives
and health insurance coverage to survive up with TB ill-
ness. Similar to a study reported from Nigeria [3], TB
patients who came from rural were more likely to dis-
burse high OOP payments compared to urban residents,
and patients who covered OOP payments by themselves
were less likely to pay high cost compared to those
whose OOP payments were covered by friends or other
relatives.
Among healthcare financing mechanism, the poten-
tial strategies in Ethiopia, which were in use to protect
patients from catastrophic costs were community
based and social health insurance schemes [39]. In this
study, only 9.7 % of TB patients had health insurance
scheme, and they were trying to cope TB costs through
loan and selling and leasing household properties. This
catastrophic cost plus the consistent rise in the cost of
living in Ethiopia, urges for comprehensive health
insurance coverage of TB patients, with optimal bal-
ance of resource allocation between prevention and
treatment. The Essentials of implementing the end-TB
strategy emphasizes that transitioning from “stopping
TB” to “ending the TB epidemic” will call for major
transformations in national TB control efforts [40]. To
this end, TB patients in HBCs such as Ethiopia with
lower income need financial protection which should
go beyond cost coverage for ant-TB drugs for patients
to withstand high costs of TB illness. Though locally
effective solutions such as national stop TB partnership
were found to be promising in HBCs such as India,
global level policy advises on most of the important el-
ements of the TB elimination efforts are required to
meet the global target of Zero TB-affected families fa-
cing catastrophic costs due to TB and 95 % reduction
of TB deaths by 2035.
The study had some limitations in that it did not
analyze costs patients incurred after TB treatment com-
pletion time and did not analyze social cost that cannot
be determined in monetary bases. The study didn’t make
other measures of poverty, such as house material or as-
sets which would provide additional information on the
overall ability of TB patients to withstand catastrophic
costs. Despite this, the study clearly shows the total cost
of TB illness to patients, guardian costs, hospitalization
costs, health insurance coverage, catastrophic costs, cop-
ing costs and implication of costs of TB illness to pa-
tients who were on TB treatment at health facilities
under DOT strategy.
Conclusion
From this study, TB patients were suffering from OOP
payments with catastrophic consequences. Additional
food cost and frequency of follow-up for directly-observed
therapy constituted high proportion and exert strong drive
to high cost. TB patients had limited financial protection
which results in adverse consequences such as borrowing
money, selling good, income loss, productivity drop and
household expenditure escalation. The economic conse-
quences were beyond TB patients and their family; it
reached to neighbors, relatives, and the community as
well. Thus, TB patients in resource-limited countries de-
serve integrated patient-centered care with comprehensive
health insurance coverage, financial incentives and nutri-
tion support to reduce catastrophic costs and retain them
in care. Such countries should induce home-based TB
care programs to reduce catastrophic costs due to attend-
ing health facility, intensify home treatment of critically-ill
patients with impaired mobility, help patients engage in
key aspects of their daily lives, and reduce the spread of
TB due to patients traveling to seek TB care.
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